ClinicalTrials.gg
TerminatedNCT00698581Updated Jul 11, 2018Results posted

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

A Phase 3 interventional study of Brivaracetam and Brivaracetam in Epilepsy, sponsored by UCB Pharma. Terminated at 53 sites in 7 countries. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-07-11.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Why this study was terminated
An interim analysis revealed the study was unlikely to attain a positive outcome for the efficacy analysis. No safety concerns were detected.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
16 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
18th of 34
88 · median 94
Started
2008
with 3 others
Phase 3
21 of 34
1 open now
Registered
11th of 34
by date
Lead sponsor
13 of 34
UCB Pharma

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 18th largest by enrollment, is one of 4 that started in 2008, is one of 21 in phase 3, and was the 11th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

Antiepileptic drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy. The objective of this study is to evaluate the efficacy of Brivaracetam (BRV) in the conversion of partial onset seizure patients from combination treatment to monotherapy

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy; Monotherapy
  • Partial Onset Seizures
  • Adults and Adolescents
04

Who can participate

Ages eligible
16 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects from 16 to 75 years, both inclusive
  • Well-characterized focal epilepsy or epileptic syndrome
  • Subjects having at least 2 but not exceeding 40 partial onset seizures, whether or not secondarily generalized per 4 weeks during the 8-week Baseline Period
  • Subjects on a stable dose of at least 1 but no more than 2 concomitant Antiepileptic Drugs (AEDs) with the second AED ≤ 50 % of the minimum recommended maintenance dose

Exclusion criteria

Exclusion Criteria:

  • Seizure type IA non-motor as only seizure type
  • History or presence of seizures occurring too frequently or indistinctly separated to be reliably counted during the 6 months preceding Visit 1 or during Baseline
  • Other serious uncontrolled disease
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Brivaracetam 50 mg

    50 mg/day

    Drug: Brivaracetam

  • Experimental
    Brivaracetam 100 mg

    100 mg/day

    Drug: Brivaracetam

Interventions

  • 25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)

    Also known as: ucb 34714

  • 25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)

    Also known as: ucb 34714

06

What researchers measure

Primary outcomes

  1. The Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase

    The cumulative exit rate was estimated using Kaplan-Meier methods and was based on the duration between start of the Evaluation Period (EP) and the earliest date the first exit criterion was met for each subject. Subjects completing the EP without meeting an exit criterion were censored on Day 112. The primary comparison was BRV 50 mg/day vs a historical control. The upper limit of the 2-sided 95 % Confidence Interval for the estimate was compared to the historical lower bound estimate of 0.722.

    Time frame: From Week 1 up to Week 17

Secondary outcomes

  1. The Number of Patients Reporting at Least One Treatment-Emergent Adverse Event (TEAE) During the Course of the Study

    Time frame: Baseline through Re-conversion (approximately 31 weeks)

  2. The Number of Patient Withdrawal Due to Adverse Events (AEs) During the Course of the Study

    Time frame: Baseline through Re-conversion (approximately 31 weeks)

  3. The Number of Patients Reporting at Least One Serious Adverse Event (SAE) During the Course of the Study

    Time frame: Baseline through Re-conversion (approximately 31 weeks)

07

Results

Posted Apr 13, 2016

Participant flow

This study started to enroll patients in August 2008 and concluded in February 2010.

Participant flow — Overall Study
MilestoneBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Started6820
Completed238
Not completed4512
Withdrew: Lack of efficacy2311
Withdrew: Withdrawal by subject60
Withdrew: Other reason91
Withdrew: Sae, non-fatal10
Withdrew: Ae, non-serious non-fatal40
Withdrew: Sae, non-fatal+ae, non-serious non-fatal10
Withdrew: Ae of unknown type10

Outcome measures

PrimaryThe Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase

The cumulative exit rate was estimated using Kaplan-Meier methods and was based on the duration between start of the Evaluation Period (EP) and the earliest date the first exit criterion was met for each subject. Subjects completing the EP without meeting an exit criterion were censored on Day 112. The primary comparison was BRV 50 mg/day vs a historical control. The upper limit of the 2-sided 95 % Confidence Interval for the estimate was compared to the historical lower bound estimate of 0.722.

Time frame:
From Week 1 up to Week 17
Reported as:
Number · proportion of subjects
The Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase
proportion of subjectsEfficacy Analysis Set (BRV 50 mg/Day Treated Subjects)
The Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase0.487 (0.347 to 0.626)
SecondaryThe Number of Patients Reporting at Least One Treatment-Emergent Adverse Event (TEAE) During the Course of the Study
Time frame:
Baseline through Re-conversion (approximately 31 weeks)
Reported as:
Number · Participants
The Number of Patients Reporting at Least One Treatment-Emergent Adverse Event (TEAE) During the Course of the Study
ParticipantsBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
The Number of Patients Reporting at Least One Treatment-Emergent Adverse Event (TEAE) During the Course of the Study5311
SecondaryThe Number of Patient Withdrawal Due to Adverse Events (AEs) During the Course of the Study
Time frame:
Baseline through Re-conversion (approximately 31 weeks)
Reported as:
Number · Participants
The Number of Patient Withdrawal Due to Adverse Events (AEs) During the Course of the Study
ParticipantsBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
The Number of Patient Withdrawal Due to Adverse Events (AEs) During the Course of the Study92
SecondaryThe Number of Patients Reporting at Least One Serious Adverse Event (SAE) During the Course of the Study
Time frame:
Baseline through Re-conversion (approximately 31 weeks)
Reported as:
Number · Participants
The Number of Patients Reporting at Least One Serious Adverse Event (SAE) During the Course of the Study
ParticipantsBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
The Number of Patients Reporting at Least One Serious Adverse Event (SAE) During the Course of the Study50

Adverse events

Collected over Adverse Events (AEs) were collected from Visit 1 (Week -8) over the BRV Add-On Period and Evaluation Period up to the end of the Re-conversion Follow-up Period (Week 23).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brivaracetam 50 mg/Day—5/68 (7.4%)33/68 (48.5%)
Brivaracetam 100 mg/Day—0/20 (0%)10/20 (50%)
Most frequent serious events
Most frequent serious events
EventBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Grand mal convulsionNervous system disorders2/680/20
PneumoniaInfections and infestations1/680/20
DizzinessNervous system disorders1/680/20
Loss of consciousnessNervous system disorders1/680/20
ParaesthesiaNervous system disorders1/680/20
Status epilepticusNervous system disorders1/680/20
AnxietyPsychiatric disorders1/680/20
Most frequent other events
Showing 10 of 14
Most frequent other events
EventBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
ConvulsionNervous system disorders3/684/20
HeadacheNervous system disorders9/680/20
DepressionPsychiatric disorders7/680/20
NauseaGastrointestinal disorders3/682/20
FatigueGeneral disorders5/682/20
Urinary tract infectionInfections and infestations1/682/20
Pain in extremityMusculoskeletal and connective tissue disorders2/682/20
DizzinessNervous system disorders0/682/20
Hot flushVascular disorders0/682/20
Decreased appetiteMetabolism and nutrition disorders6/681/20

Baseline characteristics

Demographics refer to the Randomized Set (RS).

Age, Continuous
Age, Continuous(years)Brivaracetam 50 mg/DayBrivaracetam 100 mg/DayTotal Title
Mean37.7 ± 11.743.6 ± 13.239.0 ± 12.2
Age, Customized
Age, Customized(participants)Brivaracetam 50 mg/DayBrivaracetam 100 mg/DayTotal Title
< 65 years661985
>= 65 years213
Sex: Female, Male
Sex: Female, Male(Participants)Brivaracetam 50 mg/DayBrivaracetam 100 mg/DayTotal Title
Female33841
Male351247
08

Study locations

53 sites
  • Phoenix, Arizona, United States
  • Fresno, California, United States
  • Pasadena, California, United States
  • Denver, Colorado, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Conyers, Georgia, United States
  • Macon, Georgia, United States
  • Peoria, Illinois, United States
  • Lexington, Kentucky, United States
  • Burlington, Massachusetts, United States
  • Las Vegas, Nevada, United States
  • Summit, New Jersey, United States
  • Bronx, New York, United States
  • Mineola, New York, United States
  • New York, New York, United States
  • Hickory, North Carolina, United States
  • Kettering, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Germantown, Tennessee, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • Danville, Virginia, United States
  • Charleston, West Virginia, United States
  • Waukesha, Wisconsin, United States
  • Chatswood, New South Wales, Australia
  • Adelaide, South Australia, Australia
  • Clayton, Victoria, Australia
  • Fitzroy, Victoria, Australia
  • Parkville, Victoria, Australia
  • West Heidelberg, Victoria, Australia
  • Gent, Belgium
  • Kortrijk, Belgium
  • Calgary, Alberta, Canada
  • Edmonton, Alberta, Canada
  • Toronto, Ontario, Canada
  • Windsor, Ontario, Canada
  • Sakaskatoon, Saskatchewan, Canada
  • Brno, Czechia
  • Litomysl, Czechia
  • Ostava, Czechia
  • Ostrava-Trebovice, Czechia
  • Praha 2, Czechia
  • Praha-4, Czechia
  • Aschaffenburg, Germany
  • Halle (Saale), Germany
  • Mainz, Germany
  • Regensburg, Germany
  • Goteborg, Sweden
  • Lund, Sweden
  • Stockholm, Sweden
  • Uppsala, Sweden
09

References and documents

Publications

  • Arnold S, Badalamenti V, Diaz A, Gasalla T, McShea C, Whitesides J, Fakhoury T. Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies. Epilepsy Res. 2018 Mar;141:73-82. doi: 10.1016/j.eplepsyres.2018.02.005. Epub 2018 Feb 12. PubMed 29486396 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jan 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 6 years 3 months after primary completion. A results delay was requested in Feb 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2008
First posted
Jun 17, 2008
Start
Aug 2008
Primary completionActual
Jan 2010
CompletionActual
Feb 2010
Results delay requested
Feb 9, 2011
Results first posted
Apr 13, 2016
Last update
Jul 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00698581
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jun 17, 2008
Start date
Aug 2008
Primary completion
Jan 2010
Completion
Feb 2010
Results posted
Apr 13, 2016
Last update
Jul 11, 2018

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion